The two published human studies (both DAC) The pivotal human data come from a randomized, double-blind, placebo-controlled ascending-dose study by Teichman and colleagues in healthy adults
The scope encompasses cadmium-induced hepatotoxicity, the exacerbating effects of co-exposures such as microplastics, and the protective roles of agents including luteolin and fermented Chinese herbal medicine (FCHM)
Neuron 50:897909 [DOI] [PubMed] [Google Scholar] Wright JW, Clemens JA, Panetta JA, Smalstig EB, Weatherly LA, Kramr EA, Pederson ES, Mungall BH, Harding JW
Incretin-based drugs and the risk of gallbladder or biliary tract diseases
Understanding the physiology of natural GLP-1 provides essential context for appreciating why pharmaceutical modifications were necessary to harness its therapeutic potential for chronic disease management, particularly in type 2 diabetes and obesity treatment
Parallel moves in Canada and Australia indicate that employers worldwide are replicating the value-based blueprint to manage chronic-disease liability
